Rezolute (RZLT) Projected to Post Quarterly Earnings on Thursday

Key Points

• Rezolute is expected to report Q1 2027 results before market open on November 5. Analysts project a loss of $0.18 per share and revenue of approximately $1.12 million; the earnings call is scheduled for November 6.
• The company previously reported a larger-than-expected quarterly loss of $0.20 per share versus the $0.15 consensus estimate. Analysts expect full-year and next-year losses of $0.63 and $0.40 per share, respectively.
• Wall Street remains broadly bullish: 12 analysts rate the stock a Buy and two rate it Sell, producing a Moderate Buy consensus and an average price target of $11.22, compared with a recent share price of $4.22.

Rezolute (NASDAQ:RZLT - Get Free Report) is projected to issue its Q1 2027 results before the market opens on Thursday, November 5th. Analysts expect Rezolute to post earnings of ($0.18) per share and revenue of $1.12 million for the quarter. Parties may review the information on the company's upcoming Q1 2027 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). On average, analysts expect Rezolute to post ($0.63) EPS for the current fiscal year and ($0.40) EPS for the next fiscal year.

Rezolute Stock Performance

RZLT stock opened at $4.22 on Thursday. The company has a market capitalization of $408.20 million, a PE ratio of -5.55 and a beta of 0.53. Rezolute has a one year low of $1.07 and a one year high of $11.46. The company's 50 day moving average price is $4.28 and its two-hundred day moving average price is $3.87.

Wall Street Analyst Weigh In

RZLT has been the topic of several recent research reports. HSBC raised shares of Rezolute to a "buy" rating in a report on Friday, September 25th. HC Wainwright boosted their price target on shares of Rezolute from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, September 25th. Citigroup reissued a "market outperform" rating on shares of Rezolute in a research note on Thursday, October 15th. Lake Street Capital upped their price target on shares of Rezolute from $9.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday, October 6th. Finally, Craig Hallum upgraded shares of Rezolute from a "hold" rating to a "buy" rating and upped their price target for the company from $4.00 to $7.00 in a research report on Tuesday, September 29th. Twelve research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $11.22.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company's lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.